Full Text View
Tabular View
No Study Results Posted
Related Studies
High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients
This study has been terminated.
( Very difficult to recruit patients/slow recruitment(2 patients in nearly 2 years). )
Study NCT00313547   Information provided by Montreal Heart Institute

First Received on April 10, 2006.   Last Updated on May 2, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypertension
Additional conditions recognized in this trial
Coronary Artery Disease
Glucose Intolerance
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Coronary Disease
Glucose Metabolism Disorders
Heart Diseases
Hyperglycemia
Metabolic Diseases
Myocardial Ischemia
Vascular Diseases
Interventions listed in this trial
Quinapril 40 mg
Quinapril 10 mg and amlodipine 5 mg
Additional drug interventions recognized in this trial
Amlodipine
Quinapril
More general drug interventions related to this trial
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Calcium Channel Blockers
Cardiovascular Agents
Enzyme Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Montreal Heart Institute
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services